

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
29 February 2024 (29.02.2024)



(10) International Publication Number
WO 2024/042061 A1

(51) International Patent Classification:

A61K 31/397 (2006.01) A61P 9/00 (2006.01)
A61K 31/506 (2006.01) A61K 9/00 (2006.01)

(21) International Application Number:

PCT/EP2023/073000

(22) International Filing Date:

22 August 2023 (22.08.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/399,755 22 August 2022 (22.08.2022) US
PCT/EP2022/075957

19 September 2022 (19.09.2022) EP

63/483,574 07 February 2023 (07.02.2023) US

63/501,313 10 May 2023 (10.05.2023) US

(71) Applicant: NEWAMSTERDAM PHARMA B.V. [NL/NL]; Gooimeer 2-35, 1411 DC Naarden (NL).

(72) Inventors: CRAIG, Joanne Lesley; Gooimeer 2-35, 1411 DC Naarden (NL). CUI, Sheng; Gooimeer 2-35, 1411 DC Naarden (NL). DAVIDSON, Michael Harvey; Gooimeer 2-35, 1411 DC Naarden (NL). DITMARSCH, Marc; Gooimeer 2-35, 1411 DC Naarden (NL). KASTELEIN, Johannes Jacob Pieter; Gooimeer 2-35, 1411 DC Naarden (NL).

(74) Agent: NEDERLANDSCH OCTROOIBUREAU; P.O.Box 29720, 2502 LS The Hague (NL).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.


(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: OBICETRAPIB AND EZETIMIBE COMBINATION TREATMENT AND FIXED DOSE PHARMACEUTICAL COMPOSITIONS

Fig. 1



(57) Abstract: The present disclosure relates to stable pharmaceutical compositions comprising fixed dose combination of obicetrapib and ezetimibe, or their salts, solvates or derivatives thereof. The disclosure further describes the use of ezetimibe and obicetrapib, e.g. in the form of such fixed dose combinations, for preparation of medicaments and method of treatment of subjects requiring reduction in LDL-cholesterol or those suffering from hyperlipidemia or mixed dyslipidemia.

WO 2024/042061 A1